Word-Of-Mouth is one of the oldest and successful marketing tools and Matthew Wolfson, founder and CEO of Electromedical Technologies, Inc. EMED believes that it will add to sales via the effective performance of his WellnessPro+ and other devices in his line that offer relief to acute and chronic pain through bioelectronics and electro-modulation. He has invested $4.2 million to build 1,200+ devices for inventory anticipating a boom in sales in 2021. He is determined to meet greater demand for the devices next year, much of it created by word-of-mouth he says.
The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. EMED, Medtronic PLC MDT, Nevro Corp. NVRO, Axsome Therapeutics, Inc. AXSM. GlaxoSmithKline GSK, Abbott Laboratories TBA, Eli Lilly LLY, Boston Scientific Corporation BSX, Novartis AG NVS, Johnson & Johnson JNJ and Bristol-Myers Squibb BMY.
Word-Of-Mouth A Key Marketing Tool For Electromedical Technologies, Inc. EMED For Its FDA Cleared WellnessPro+ Device Which Relieves Chronic Pain Through Bioelectronics; EMED Spends $4.2 Million As It Builds 1,200+ Unit Inventory In Preparation For Attracting Hundreds More Medical Practitioners And Distributors In 2021
Wolfson said, "In the world we live in today, people cannot afford the risks associated with opioid-based drugs, but they need results. Word of mouth has been a very valuable marketing tool because our device delivers a powerful solution to chronic pain without any dangerous or harmful side effects. The Wellness Pro produces real results so people can live pain free and get their lives back!"
Pandemic Environment Intensifies Why Patients Do Not Seek Invasive Treatments Or Opioids Which Can Have Harmful Side Effects
Prescription pharmaceuticals can have the harmful side effect of opioid addiction. Anticipating the on-boarding of hundreds of new medical practitioners and distributors, EMED is building up inventory of the devices as it transitions into 2021. The Company has paid in full for the inventory it built to ensure it has enough product to meet demand. Matthew Wolfson sees word-of-mouth endorsements of his Wellness Pro devices as valuable and driving greater sales because they work and provide relief from sufferers of chronic, acute and intractable pain. Word quickly spreads about these devices from actual results.
Inventory Build Up Is A Strategic Strategy Of Electromedical Technologies, Inc. EMED
For 2021, Wolfson believes that patients who have experienced chronic pain relief from the bioelectronics and electro-modulation the Wellness Pro devices deliver — and the word-of-mouth from them and their observers — warrants the inventory build-up in anticipation of on boarding hundreds of additional medical practitioners and distributors. The end result is that word-of-mouth is a valuable and effective marketing tool. Word-Of-Mouth A Key Marketing Tool For Electromedical Technologies, Inc. EMED For Its FDA Cleared WellnessPro+ Device Which Relieves Chronic Pain Through Bioelectronics; EMED Spends $4.2 Million As It Builds 1,200+ Unit Inventory In Preparation For Attracting Hundreds More Medical Practitioners And Distributors In 2021.
The WellnessPlus Pod Is Coming
The good news keeps coming for Electromedical Technologies, Inc. EMED as its newest product, the WellnessPro Pod, is expected to be ready by Electromedical Technologies, Inc. EMED after anticipated FDA clearance by late 2021. The WellnessPlus POD is a smaller, professional, less costly device that features a special portal for telemedicine-like real time monitoring by physicians. the WellnessPro POD, links doctors and patients with that feature and is less costly, smaller, portable and offers the remote POD portal. It also offers a unique financial sales structure for the Company, combining a down payment purchase with a prescription, plus a monthly subscription services fee.
Goldman Small Cap Research Yesterday Set A $5.70 12-Month Price Target For Electromedical Technologies, Inc. EMED
Anticipating a surge in demand in 2021 comes as Goldman Small Cap Research this week set a $5.70 12-Month Price Target For Electromedical Technologies, Inc. EMED, in its Opportunity Research report. The investment analysis projects that the medical device company will reach volumes of $1.55 Million in FY2021 and $17 Million in FY2022 and projects EMED will sell some 80,000 devices in 2022. It is bullish on sales prospects for the WellnessPlus Pod. It especially values the telemedicine portal feature and real-time treatment views to medical professionals.
EMED Offers Income Opportunity Via Its Brand Ambassador Program
Matthew Wolfson also invited consumers to create new revenue streams for their families by joining the Company's Brand Ambassador Program. We have a way to help thousands of people to live a better quality of life, pain free and addiction free and at the same time provide a real income opportunity for anyone who wishes to join our brand ambassador team. If interested, they can learn more here. Word-Of-Mouth A Key Marketing Tool For Electromedical Technologies, Inc. EMED For Its FDA Cleared WellnessPro+ Device Which Relieves Chronic Pain Through Bioelectronics; EMED Spends $4.2 Million As It Builds 1,200+ Unit Inventory In Preparation For Attracting Hundreds More Medical Practitioners And Distributors In 2021.
Source: Stock Market Press
Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.
Contact:
Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:
Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
See Stock Market Press disclaimer: http://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
